All In Biotech

NDA 212379 · Journey

Amzeeq

Minocycline Hydrochloride · Topical

Last checked: Nov 20, 2026Latest source record: Jan 13, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Oct 18, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

291

55 Phase 3, 18 recruiting

FAERS reports

11,701

8,940 serious, 1,645 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 1, 2023.

AMZEEQ is indicated for the topical treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older [ see Clinical Studies ( 14 ) ]. Limitations of Use This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, AMZEEQ should be used only as indicated [ see Warnings and Precautions ( 5.14 ) ]. AMZEEQ is a tetracycline-class drug indicated to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. ( 1 ) Limitations of Use This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, AMZEEQ should be used only as indicated. ( 5.14 )

Mechanism: The mechanism of action of AMZEEQ for the treatment of acne is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • AMZEEQ · MINOCYCLINE HYDROCHLORIDE EQ 4% BASE · AEROSOL, FOAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Minocycline" as an intervention, any sponsor and status, largest first.

All 291 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,981
  • off label use1,488
  • nausea1,077
  • pain1,021
  • arthralgia1,003
  • fatigue962
  • drug intolerance913
  • rash910
  • drug hypersensitivity907
  • rheumatoid arthritis879
  • joint swelling874
  • headache804

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200411
200552
20067
20072
20086
200979
201086
201199
2012233
2013416
2014431
2015539
2016806
2017871
2018894
20191,144
20201,038
2021780
2022704
2023882
20241,205
2025974
2026442

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Amzeeq (Minocycline HCl)

2024 spending

$368K

Beneficiaries

364

764 claims

Per beneficiary

$1,012

$15.73 per unit

View as table
YearSpending
2020$0
2021$0
2022$22,882
2023$334,981
2024$368,485

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 690 on PubMed

Sponsor: Journey

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.